Arch Therapeutics Inc (ARTH): Price and Financial Metrics

Arch Therapeutics Inc (ARTH)

Today's Latest Price: $0.17 USD

0.00 (-1.19%)

Updated Nov 27 8:28pm

Add ARTH to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 143 in Medical - Devices & Equipment

See all "A" rated Strong Buy stocks

ARTH Stock Price Chart Interactive Chart >

Price chart for ARTH

ARTH Price/Volume Stats

Current price $0.17 52-week high $0.30
Prev. close $0.17 52-week low $0.13
Day low $0.16 Volume 57,400
Day high $0.17 Avg. volume 289,073
50-day MA $0.17 Dividend yield N/A
200-day MA $0.18 Market Cap 32.03M

Arch Therapeutics Inc (ARTH) Company Bio

Arch Therapeutics, Inc. operates as a life science medical device company. The company develops products based on its technology to stop bleeding and control leaking, as well as provides other advantages during surgery and trauma care. Its primary product candidate is AC5 Devices, a biocompatible synthetic peptide that comprises naturally occurring amino acids to achieve hemostasis in minimally invasive and open surgical procedures. The company was founded in 2006 and is based in Framingham, Massachusetts.

ARTH Latest News Stream

Event/Time News Detail
Loading, please wait...

ARTH Latest Social Stream

Loading social stream, please wait...

View Full ARTH Social Stream

Latest ARTH News From Around the Web

Below are the latest news stories about Arch Therapeutics Inc that investors may wish to consider to help them evaluate ARTH as an investment opportunity.

Arch Therapeutics' AC5 Heals Recalcitrant Diabetic Foot Ulcer

In this recent article, I covered a severe pressure ulcer case treated by AC5 from Arch Therapeutics (ARTH). AC5 is a wound care and bleeding control technology that is approved by both the Food & Drug Administration and the European Medicines Agency for external use. Arch is seeding Key Opinion...

Michael Murphy, CFA on Seeking Alpha | September 22, 2020

Arch Therapeutics Reports First Pressure Ulcer Case Results

I introduced Arch Therapeutics (ARTH), the inventors of the AC5 wound care and bleeding control technology, to Seeking Alpha readers in this article when the company had no approved product, no revenues, and a market capitalization of only $21.0 million. I updated readers after the company received its first FDA...

Michael Murphy, CFA on Seeking Alpha | September 12, 2020

Arch Therapeutics, Inc. to Present at the Virtual Investor Fireside Chat Series

FRAMINGHAM, Mass., June 08, 2020 -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel wound care and biosurgical devices, today announced that.

Yahoo | June 8, 2020

Arch Raises $1.4 Million with Convertible Note Issuance and Warrant Reprice

As part of the capital raising, the Company has issued a Series 1 Unsecured Convertible Note (the “Note”) to several accredited current investors for the aggregate principal amount of $550,000. Features of the note allow for payment of principal plus accrued interest at any time up until maturity as well as conversion into common stock under certain conditions (to “Convert”) at a price of $0.27 per share (“Conversion Price”). The Company may Convert upon raising $5M of equity capital at the Conversion Price or greater or after the stock trades above $0.32 per share for at least 15 days on a volume weighted basis.

Yahoo | June 5, 2020

Arch Therapeutics to Provide Corporate Update at the Virtual Summer Summit

FRAMINGHAM, Mass., June 03, 2020 -- Arch Therapeutics, Inc. (OTCQB: ARTH) ("Arch" or the "Company"), developer of novel wound care and biosurgical devices, will be featured as.

Yahoo | June 3, 2020

Read More 'ARTH' Stories Here

ARTH Price Returns

1-mo 0.00%
3-mo 1.92%
6-mo -22.02%
1-year -40.97%
3-year -72.13%
5-year -30.61%
YTD -31.89%
2019 -52.91%
2018 23.26%
2017 -26.31%
2016 188.86%
2015 0.05%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from!

Page generated in 0.6862 seconds.